Man with macular degeneration has his eye's retina examined during a check-up in Boston, United States
Keystone
A court in Germany has ruled in favour of the Swiss pharmaceutical company Novartis in a long-running legal case over the distribution of a drug to slow age-related vision loss.
This content was published on
1 minute
swissinfo.ch and agencies
Judges in Hamburg found the German company Aposan must not sell pre-filled syringes for €600 (CHF741) partly containing the Lucentis drug, said court officials on Tuesday.
The medication for the treatment of macular degeneration is distributed by Novartis in bottles of at a cost of €1,200. In the United States the drug is marketed by the Swiss pharmaceutical firm Roche.
Novartis said the verdict by the German court helped ensure patient safety. Worldwide sales of Lucentis totalled $2.4 billion in 2012.
Experts say the ruling could set a legal precedent for health insurance companies trying to cut rising drug prices.
The verdict is subject to an appeal.
Popular Stories
More
Swiss Politics
Swiss reject plans for bigger motorways and extra rights for landlords
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
US, Japan file complaints against Novartis
This content was published on
The New Jersey-based company boosted its sales of the iron-reduction drug Exjade by giving referrals and rebates to pharmacy BioScrip, which recommended refills to its patients but often failed to warn them of the drug’s potentially fatal side effects. These include kidney failure and gastrointestinal haemorrhaging, according to the complaint filed in Manhattan federal court…
This content was published on
The European Commission said that Johnson & Johnson had paid Novartis for delaying the sale of a cheaper version of a painkiller, which had lost patent protection in July 2005, for 17 months. Johnson & Johnson was hit by a CHF13.1 million fine, while Basel-based pharma company Novartis will have to stump up CHF6.7 million.…
This content was published on
Barcelona-based Grifols, the world’s third-largest blood products maker, said on Monday its diagnostics unit would make up 20% of its revenues after the deal, up from 4% now, and that annual turnover in the business would grow to around $1 billion. The diagnostic business focuses on ensuring the safety of blood transfusions. “The sale of…
This content was published on
According to the board of directors of the Basel-based pharma giant, Vasella will receive $5.2 million in cash and unrestricted shares for eight months’ work this year assisting with the transition to his successor. He will also get a guaranteed minimum fee of $250,000 a year from 2014 through 2016 just to be available for…
This content was published on
Inside the lofty glass entrance hall of the former headquarters of Merck Serono in Geneva you can hear a pin drop. “The last staff members left last week,” explains the lone receptionist. Just over one year ago the German drug and chemical maker Merck dropped a biotech bombshell when it announced it was closing its…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.